UNSPSC 51332840: Chlorpromazine hydrochloride

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19ClN2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9WP59609J6, chemically known as 10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, radical ion(1+) but more generally known as chlorpromazine hydrochloride, which bears US NIH Compound Identifier 2726. European Medicines Agency schedules Chlorpromazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01255MIG.

UNSPSC 51332840 Chlorpromazine hydrochloride is a Commodity code that appears to capture specific pharmaceutical products; however, the recent state and local opportunities tagged under this code show minimal activity directly aligned with chlorpromazine procurement. Instead, the opportunities reflect broader pharmaceutical and over-the-counter product sourcing by state health agencies and cooperative purchasing alliances, including naloxone, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. The issuing bodies soliciting under or near this code include state health departments (Texas Health and Human Services Commission), county public health agencies (Seminole County, Florida), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The work being bought centers on competitive bidding for pharmaceutical inventory, generic drug product sourcing through authorized wholesaler channels, and exploratory market intelligence on direct-to-manufacturer prescription fulfillment models to support state employee health plans and community health initiatives.

Recent activity spans Florida, Texas, and Minnesota, with the Minnesota MMCAP cooperative purchasing vehicle offering the broadest geographic reach across participating state and local government facilities. The Seminole County IFB (solicitation number IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year contract term and one-year renewal option. The Texas HHS Commission issued an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The MMCAP RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, requiring vendor compliance with cGMP, the Drug Supply Chain Security Act, and pricing submission in competitive net pricing formats, with contract effectiveness July 1, 2026.